Correction: PAK4 inhibition enhances the efficacy of PD-1 blockade immunotherapy

By
Gabriel Abril-Rodriguez
Davis Y. Torrejon
Wei Liu
Jesse M. Zaretsky
Theodore S. Nowicki
Jennifer Tsoi
Cristina Puig-Saus
Ignacio Baselga-Carretero
Egmidio Medina
Michael J. Quist
Alejandro J. Garcia
William Senapedis
Erkan Baloglu
Anusha Kalbasi
Gardenia Cheung-Lau
Beata Berent-Maoz
Begoña Comin-Anduix
Siwen Hu-Lieskovan
Cun-Yu Wang
Catherine S. Grasso
Antoni Ribas
October 9, 2026

Nature Cancer

At a Glance

Category	Detail
Condition	PAK4 inhibition and PD-1 blockade immunotherapy
Key Mechanisms	The correction concerns reporting of mouse group sizes in experiments involving PAK4 knockout, anti-PD-1 treatment, and anti-CD8 treatment.
Target Population	Mice in the experiments reported in Fig. 5.
Care Setting	Preclinical experimental research.

Key Highlights

The correction was published online on 9 December 2019.
The initial Fig. 5 legend and source data file did not state that the n = 16 mice per group in Fig. 5a were pooled across three independent experiments.
Fig. 5d showed one experiment with n = 6 mice in each of the PAK4 KO isotype and PAK4 KO anti-PD1 groups.
Fig. 5d also included a PAK4 KO anti-PD1 anti-CD8 group with n = 5 mice.
The legend and associated source data file were amended, and the correction was incorporated into the HTML and PDF versions.

Guideline-Based Recommendations

Diagnosis

Management

Monitoring & Follow-up

Risks

Patient & Prescribing Data

No human patient population or prescribing data are described; the correction concerns mouse experiments.

The correction identifies experimental groups receiving PAK4 knockout, isotype control, anti-PD-1, and anti-CD8 treatment; it does not provide clinical prescribing guidance.